Literature DB >> 7143688

Wide interpatient variations in gentamicin dose requirements for geriatric patients.

D E Zaske, P Irvine, L M Strand, R G Strate, R J Cipolle, J Rotschafer.   

Abstract

Substantial interpatient variations were demonstrated in the daily doses required to obtain therapeutic gentamicin sulfate serum concentrations in 417 elderly patients. Dosages ranged from 0.3 to 22.0 mg/kg/day in patients with a normal serum creatinine level. Twenty-five percent of these patients required daily doses higher than the standard regimen of 5 mg/kg/day, and 33% required less than 3 mg/kg/day. The drug half-lives in these patients ranged from 0.3 to 32.7 hours, compared with previous reports of 2.5 to four hours. The distribution volumes of these patients ranged from 0.07 to 0.53 L/kg, compared with reported values of 0.20 to 0.25 L/kg. These wide variations in kinetic variables in elderly patients and the need to obtain narrow ranges in serum concentrations required measuring serum concentrations and individually calculating each patient's dosage requirement early in the treatment course. Doing this consistently produced optimal peak and trough serum levels. Ototoxicity did not occur in any of the patients, and nephrotoxicity may have been drug related in 2% of the elderly patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7143688

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  13 in total

Review 1.  Cost-effectiveness of therapeutic drug monitoring.

Authors:  S Vozeh
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 2.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

3.  Severe rombergism due to gentamicin toxicity.

Authors:  D G Swain
Journal:  Br Med J (Clin Res Ed)       Date:  1987-12-12

Review 4.  Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?

Authors:  M M Tod; C Padoin; O Petitjean
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly.

Authors:  E Triggs; B Charles
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

6.  Comparison of non-kinetic and kinetic approaches to individualization of gentamicin dosage.

Authors:  Y M el-Sayed; S I Islam
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Increased aminoglycoside dosage requirements in hematologic malignancy.

Authors:  R G Zeitany; N S El Saghir; C R Santhosh-Kumar; M A Sigmon
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

8.  Influence of age on amikacin pharmacokinetics in patients without renal disease. Comparison with gentamicin and tobramycin.

Authors:  L A Bauer; R A Blouin
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 9.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

10.  Aminoglycoside forecasting in neutropenic patients with cancer.

Authors:  J L Kosirog; R M Rospond; C Destache; P Hall
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.